Bioinformatics Methods to Discover Antivirals Against Zika Virus
Zika virus is a member of the Flaviviridae virus family, similar to other viruses that affect humans, such as hepatitis C and dengue virus. After its first appearance in 1947, Zika virus reappeared in 2016 causing an international public health emergency. Zika virus was considered a non dangerous human pathogen; however, it is currently considered a pathogen with serious consequences for human health, showing association with neurological complications such as Guillain-Barre syndrome and microcephaly. Then, it is necessary to get antivirals able to inhibit the replication of the Zika virus since vaccines for this virus are not yet available. Zika virus structure is similar to hepatitis C virus structure. This characteristic suggests that anti-hepatitis C virus agents can be used as alternative in treatments against the Zika virus. This work aims to determine a non-nucleoside analogue antivirals that can be considered possible antivirals against Zika virus. In this study, we used computational methods to analyze the Docking and the modeling of the NS5 polymerase of Zika virus and antivirals.
KeywordsBioinformatics Zika virus Antivirals
Authors are grateful for the support received from Universidad Nacional de Misiones, Posadas (Argentina), and the Information Technologies Innovation (ITI) Research Group, Universidad Distrital Francisco Jose de Caldas, Bogota (Colombia).
- 7.Fagbami, A.: Zika virus infections in Nigeria: virological and seroepidemiological investigations in Oyo state. Epidemiol. Infect. 83(2), 213–219 (1979)Google Scholar
- 10.Florez, H., Salvatierra, K.: Bioinformatics study of mutations of resistance to antivirals in the NS5A gen of HCV. Int. Inf. Inst. (Tokyo) Inf. 20(9), 6665–6672 (2017)Google Scholar
- 18.Organization, W.H., et al.: Zika virus research agenda (2016)Google Scholar
- 21.Penié, J.B., González-Piñera, J.G., Rodríguez, M.A.R., Alfonso, P.P.P.: Medicamentos antivirales. Acta Médica 8(1), 86–100 (1998)Google Scholar
- 25.Sacramento, C.Q., et al.: The clinically approved antiviral drug sofosbuvir impairs Brazilian Zika virus replication. BioRxiv, p. 061671 (2016)Google Scholar
- 26.Saiz, J.C., Vázquez-Calvo, Á., Blázquez, A.B., Merino-Ramos, T., Escribano-Romero, E., Martín-Acebes, M.A.: Zika virus: the latest newcomer. Front. Microbiol. 7, 496 (2016)Google Scholar
- 31.Trott, O., Olson, A.J.: Autodock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31(2), 455–461 (2010)Google Scholar
- 35.Zmurko, J., Marques, R.E., Schols, D., Verbeken, E., Kaptein, S.J., Neyts, J.: The viral polymerase inhibitor 7-deaza-2’-c-methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model. PLoS Negl. Trop. Dis. 10(5), e0004695 (2016)CrossRefGoogle Scholar